U.S. Asthma Drugs Market (By Medication: Quick Relief Medications, Long-term Control Medications, Others; By Mode of Administration: Tablets and Capsules, Liquids, Inhalers, Injections, Sprays and Powders; By Source: Environmental, Generic; By Organization Type: Public, Private; By Application: Pediatric, Adults, Adolescent)) - Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2033

U.S. Asthma Drugs Market Size and Trends

The U.S. asthma drugs market size was valued at USD 8.95 billion in 2023 and is projected to surpass around USD 14.75 billion by 2033, registering a CAGR of 5.12% over the forecast period of 2024 to 2033. 

U.S. Asthma Drugs Market Key Takeaways

• By medication, the quick relief medications segment dominated the market in 2023, the segment is observed to witness a notable growth during the forecast period.
• By mode of administration, the inhalers segment dominated the U.S. asthma drugs market in 2023. The segment is observed to sustain the position during the forecast period.
• By organization type, the public segment is expected to sustain its dominance throughout the forecast period.
• By application, the adults segment was observed to dominate the U.S. asthma drugs market in 2023.
• By application, the pediatric segment is expected to show substantial growth during the forecast period.

U.S. Asthma Drugs Market by Introduction

Asthma, a chronic respiratory condition characterized by inflammation and narrowing of the airways, presents a significant healthcare challenge in the United States. With millions affected nationwide, the demand for effective asthma management solutions has spurred the growth of the U.S. asthma drugs market. This market encompasses a wide array of pharmaceutical products aimed at alleviating symptoms, preventing exacerbations, and improving patients' quality of life. From traditional bronchodilators to newer biologic therapies, the market offers diverse treatment options catering to varying patient needs. Factors such as increasing prevalence, advancements in drug development, rising healthcare expenditure, and strategic industry initiatives all contribute to the dynamic growth trajectory of the U.S. asthma drugs market. This introductory overview sets the stage for a deeper exploration of market trends, key players, regulatory landscape, and future prospects within this critical segment of the pharmaceutical industry.

U.S. Asthma Drugs Market Growth 

The growth of the U.S. asthma drugs market is fueled by several key factors. Firstly, the increasing prevalence of asthma cases across the country drives the demand for effective treatment options. Additionally, advancements in medical research and technology have led to the development of innovative asthma medications, providing patients with more choices and improved outcomes. Furthermore, rising healthcare expenditure and growing awareness about asthma management contribute to the expansion of the market. Moreover, strategic initiatives by pharmaceutical companies, such as product launches and collaborations, play a significant role in driving market growth by expanding product portfolios and reaching a wider patient population. Overall, these factors converge to create a favorable environment for the growth of the U.S. asthma drugs market, with prospects for further expansion in the foreseeable future.

U.S. Asthma Drugs Market Report Scope

U.S. Asthma Drugs Market Trends

• Biologics Dominance: Biologic drugs, particularly monoclonal antibodies like omalizumab (Xolair), mepolizumab (Nucala), and dupilumab (Dupixent), were gaining prominence. These drugs target specific pathways in the immune system involved in asthma, offering more targeted and effective treatment for severe asthma cases.
• Technological Advances: The market was witnessing advancements in inhaler technology, with the introduction of smart inhalers that can track medication usage and provide data to both patients and healthcare providers. These devices aimed to improve adherence to medication regimens and better manage asthma symptoms.
• Personalized Medicine: There was a growing focus on personalized medicine approaches in asthma treatment. This involved genetic testing and biomarker identification to tailor treatment plans to individual patients, optimizing efficacy and minimizing side effects.
• Generic Competition: The market faced increasing competition from generic versions of traditional asthma medications like albuterol and inhaled corticosteroids. This trend was driven by patent expirations and efforts to reduce healthcare costs.
• Telemedicine Integration: Telemedicine was becoming more prevalent in asthma management, allowing patients to consult with healthcare providers remotely for routine check-ups, medication adjustments, and education on asthma self-management techniques.
• Environmental Factors: Awareness of environmental factors contributing to asthma, such as air pollution and allergens, was influencing both treatment approaches and public health initiatives aimed at reducing asthma prevalence and severity.
• Healthcare Policy Impact: Changes in healthcare policy, including drug pricing regulations and insurance coverage expansions, were shaping access to asthma medications and influencing prescribing patterns.

U.S. Asthma Drugs Market Dynamics

Driver: Growing prevalence of asthma and government initiatives

The U.S. prevalence of asthma has been on the rise, contributing to a growing patient population. This increase in the number of asthma cases is a significant driver of the demand for asthma drugs. According to an AAFA article from September 2022, there are over 25 million asthmatics in the United States. Additionally, about 15 million persons in the U.S. suffer from COPD, according to an NIH paper from March 2022. Besides, the rising initiatives by the government also propelled the market expansion in the country.

• In March 2022, a proposal that provides 8.5 billion U.S. dollars to maintain funding for CDC asthma initiatives was released by U.S. government health programs. Thirty million dollars are included for the National Asthma Control program.

Restraint: High cost

One major issue affecting the U.S. asthma drugs market is the high cost of its services and products. Many patients, particularly those with inadequate insurance coverage or those belonging to low-income communities, may find the expense of drugs, including inhalers and oral medications, to be an overwhelming burden. Subpar asthma management may result from access to essential drugs and preventative measures being restricted due to the high cost of therapy.

The research and manufacturing process of drugs is one of the factors contributing to the high cost of asthma therapy. The total cost is increased by clinical trials, regulatory approvals, and research and development. The high cost is also influenced by the ongoing need for innovation and the release of newer, more potent treatments. Thus, hampering the market growth.

Opportunity: Growing FDA approvals

The discovery of novel drugs is critical for pharmaceutical research and development and patient treatment. Repurposing existing drugs that may have anticipated effects as a potential candidate is one way to meet this vital goal. The subsequent increasing FDA approvals of these new as well as repurposed drugs is expected to offer a lucrative opportunity for the asthma drugs market growth over the forecast period.

• In February 2023, in the US, Tezspire (tezepelumab), a product of AstraZeneca and Amgen, is authorized for self-administration by patients with severe asthma who are 12 years of age or older. With its authorized label including no phenotypic (e.g., eosinophilic or allergic) or biomarker constraint, Tezspire is the only biologic licensed for severe asthma.

U.S. Asthma Drugs Market By Medication Insights

The quick relief medications segment held the largest share in 2023. Quick-relief medications, also known as rescue medications, are a crucial component of asthma management. They provide rapid relief from acute asthma symptoms by bronchodilating and easing airway constriction. Common quick-relief medications include short-acting beta-agonists (SABAs).

Advances in inhaler technologies, such as the development of smart inhalers, aim to enhance patient adherence and monitor medication usage. Smart inhalers may have the potential to impact the market by improving the management and tracking of quick-relief medication use. Thereby driving the segment growth.

U.S. Asthma Drugs Market By Mode of Administration Insights

The inhalers segment dominated the U.S. asthma drugs market in 2023. The segment is observed to sustain the position throughout the forecast period. The segment expansion is attributed to the increasing advancements in inhaler technology, including smart inhalers. The integration of digital technology into inhalers, known as smart inhalers, has been a growing trend. These devices may include sensors to track medication usage, provide reminders, and offer insights into asthma management.

• In June 2023, the Handilhale® smart inhaler, developed by OPKO Health Inc., features a built-in sensor and a mobile app to measure medicine consumption and give patients with chronic obstructive pulmonary disease (COPD) individualized insights.

U.S. Asthma Drugs Market By Organization Type Insights

The public segment dominated the U.S. asthma drugs market in 2023. Public organizations often launch health education campaigns to raise awareness about asthma, its symptoms, triggers, and the importance of proper management. These campaigns may influence public perception and encourage individuals to seek appropriate medical care, potentially impacting the demand for asthma drugs.

U.S. Asthma Drugs Market By Application Insights

The U.S. asthma drugs market is segmented into pediatric, adults, and adolescent. The adults segment dominated the market in 2023 and the segment is observed to sustain the dominance in the market during the forecast period. According to the American College of Allergy, Asthma, and Immunology, the prevalence of asthma is greater in adults (8.0%) than in children (6.5%). Such disparity promotes greater efforts for the treatment of asthma in the demographic, greatly driving the growth of the adult segment in the U.S. asthma drugs market.

The pediatric segment is expected to grow at the highest growth during the forecast period. Asthma is one of the most common chronic conditions in children. The prevalence of pediatric asthma has been increasing in the U.S. The high incidence of asthma in children contributes to the demand for asthma medications specifically designed for pediatric use.

U.S. Asthma Drugs Market Recent Developments

• In January 2023, in the United States, Airsupra (albuterol/budesonide), formerly known as PT027, received recognition as a preventive or as-needed treatment for bronchoconstriction, as well as to lower the risk of exacerbations in individuals with asthma who are 18 years of age or older. The FDA's clearance was granted based on the outcomes of the Phase III studies for MANDALA and DENALI.
• In July 2023, the U.S. Food and Drug Administration approved the first generic version of AstraZeneca's Symbicort®, BreynaTM (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol. The drug is a result of a collaboration between Viatris Inc., a global healthcare company, and Kindeva Drug Delivery L.P. It is recommended for certain people who suffer from asthma or chronic obstructive pulmonary disease (COPD).
• In December 2023, an exclusive license agreement was announced to develop a potential novel antibody-based therapy for the treatment of asthma and atopic dermatitis by Teva Pharmaceutical Industries Ltd. and Biolojic Design Ltd., a biotechnology company that turns antibodies into intelligent medicinal solutions using computational biology and artificial intelligence.

U.S. Asthma Drugs Market Top Key Companies:

• GlaxoSmithKline
• Pfizer
• Vectura Group
• Boehringer Ingelheim
• Roche
• Novartis
• Merck
• AstraZeneca
• Teva Pharmaceutical

U.S. Asthma Drugs Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. Asthma Drugs market.

By Medication

• Quick Relief Medications
• Long-term Control Medications
• Others

By Mode of Administration

• Tablets and Capsules
• Liquids
• Inhalers
• Injections
• Sprays and Powders

By Source

• Environmental
• Generic

By Organization Type

• Public
• Private

By Application

• Pediatric
• Adults
• Adolescent